251 related articles for article (PubMed ID: 37047737)
1. The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.
Blaine-Sauer S; Samuels TL; Yan K; Johnston N
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047737
[TBL] [Abstract][Full Text] [Related]
2. Amprenavir inhibits pepsin-mediated laryngeal epithelial disruption and E-cadherin cleavage in vitro.
Samuels TL; Blaine-Sauer S; Yan K; Johnston N
Laryngoscope Investig Otolaryngol; 2023 Aug; 8(4):953-962. PubMed ID: 37621274
[TBL] [Abstract][Full Text] [Related]
3. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
4. Topical Alginate Protection against Pepsin-Mediated Esophageal Damage: E-Cadherin Proteolysis and Matrix Metalloproteinase Induction.
Samuels TL; Blaine-Sauer S; Yan K; Plehhova K; Coyle C; Johnston N
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175640
[TBL] [Abstract][Full Text] [Related]
5. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
6. Does Barrett's esophagus regress after surgery (or proton pump inhibitors)?
Spechler SJ
Dig Dis; 2014; 32(1-2):156-63. PubMed ID: 24603402
[TBL] [Abstract][Full Text] [Related]
7. Oral and Inhaled Fosamprenavir Reverses Pepsin-Induced Damage in a Laryngopharyngeal Reflux Mouse Model.
Johnston N; Samuels TL; Goetz CJ; Arnold LA; Smith BC; Seabloom D; Wuertz B; Ondrey F; Wiedmann TS; Vuksanovic N; Silvaggi NR; MacKinnon AC; Miller J; Bock J; Blumin JH
Laryngoscope; 2023 Jan; 133 Suppl 1(Suppl 1):S1-S11. PubMed ID: 35678265
[TBL] [Abstract][Full Text] [Related]
8. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
Lada MJ; Nieman DR; Han M; Timratana P; Alsalahi O; Peyre CG; Jones CE; Watson TJ; Peters JH
Surgery; 2013 Oct; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
[TBL] [Abstract][Full Text] [Related]
9. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms.
Reavis KM; Morris CD; Gopal DV; Hunter JG; Jobe BA
Ann Surg; 2004 Jun; 239(6):849-56; discussion 856-8. PubMed ID: 15166964
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
11. Antireflux Surgery and Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.
Maret-Ouda J; Konings P; Lagergren J; Brusselaers N
Ann Surg; 2016 Feb; 263(2):251-7. PubMed ID: 26501714
[TBL] [Abstract][Full Text] [Related]
12. Pepsinogen/Proton Pump Co-Expression in Barrett's Esophageal Cells Induces Cancer-Associated Changes.
Stabenau KA; Samuels TL; Lam TK; Mathison AJ; Wells C; Altman KW; Battle MA; Johnston N
Laryngoscope; 2023 Jan; 133(1):59-69. PubMed ID: 35315085
[TBL] [Abstract][Full Text] [Related]
13. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
[TBL] [Abstract][Full Text] [Related]
14. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
15. Do proton pump inhibitors protect against cancer progression in GERD?
Miyashita T; Shah FA; Harmon JW; Marti GP; Matsui D; Okamoto K; Makino I; Hayashi H; Oyama K; Nakagawara H; Tajima H; Fujita H; Takamura H; Murakami M; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Ohta T
Surg Today; 2013 Aug; 43(8):831-7. PubMed ID: 23111465
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of salivary pepsin measurement in patients with proton pump inhibitor-refractory gastroesophageal reflux disease symptoms: a prospective comparative study.
Matsumura T; Arai M; Suzuki T; Hoppo T; Seki Y; Kasamatsu S; Ishigami H; Ishikawa K; Okimoto K; Akizue N; Maruoka D; Nakagawa T; Odaka T; Okamoto Y; Kato N
Esophagus; 2020 Jul; 17(3):339-347. PubMed ID: 31982992
[TBL] [Abstract][Full Text] [Related]
17. Gastroesophageal reflux disease. Are we acting in the best interest of our patients?
Tebala GD
Eur Rev Med Pharmacol Sci; 2016 Nov; 20(21):4553-4556. PubMed ID: 27874941
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.
Sharaiha RZ; Freedberg DE; Abrams JA; Wang YC
Dig Dis Sci; 2014 Jun; 59(6):1222-30. PubMed ID: 24795040
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of surgical patients with gastroesophageal reflux disease and Barrett's esophagus].
Zsolt S; Paszt A; Géczi T; Abrahám S; Tóth I; Horváth Z; Pieler J; Tajti J; Varga A; Tiszlavicz L; Németh I; Izbéki F; Rosztóczy A; Wittmann T; Lázár G
Magy Seb; 2014 Oct; 67(5):287-96. PubMed ID: 25327403
[TBL] [Abstract][Full Text] [Related]
20. How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?
de Bortoli N; Nacci A; Savarino E; Martinucci I; Bellini M; Fattori B; Ceccarelli L; Costa F; Mumolo MG; Ricchiuti A; Savarino V; Berrettini S; Marchi S
World J Gastroenterol; 2012 Aug; 18(32):4363-70. PubMed ID: 22969200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
